Bioabsorbable left atrial appendage closure with endothelialization promoting surface

Information

  • Patent Grant
  • 10667896
  • Patent Number
    10,667,896
  • Date Filed
    Friday, November 11, 2016
    7 years ago
  • Date Issued
    Tuesday, June 2, 2020
    3 years ago
Abstract
The disclosure pertains to percutaneously deliverable bioabsorbable closure devices for an ostium of a left atrial appendage which devices promote endothelialization across the ostium and then are bioabsorbed to leave little or no foreign residue, methods of manufacturing such bioabsorbable closure devices, and the use thereof.
Description
BACKGROUND

There are a number of heart diseases (e.g. coronary artery disease, mitral valve disease) that have various adverse effects on the heart. An adverse effect of certain cardiac diseases, such as mitral valve disease, is atrial (or auricular) fibrillation. Atrial fibrillation may result in pooling of blood in the left atrial appendage. Blood pooling may also be spontaneous. When blood pools in the atrial appendage, blood clots can form and accumulate therein, build upon themselves, and propagate out from the atrial appendage into the atrium. These blood clots can then enter the systemic or pulmonary circulations and cause serious problems if they migrate from the atrial appendage and become free in the blood stream and embolize distally into the arterial system. Similar problems also occur when a blood clot extending from an atrial appendage into an atrium breaks off and enters the blood supply. Since blood from the left atrium and ventricle supply the heart and brain, blood clots from the atrial appendages can obstruct blood flow therein causing heart attacks, strokes or other organ ischemia. It is therefore necessary to find a means of preventing blood clots from forming in the atrial appendages and to prevent these blood clots, once formed, from leaving the atrial appendages to the heart lungs, brain or other circulations of the patient which can cause heart attacks or strokes or other organ ischemia.


U.S. Pat. No. 5,865,791 relates to the reduction of regions of blood stasis and ultimately thrombus formation in such regions, particularly in the atrial appendages of patients with atrial fibrillation. More specifically, the invention relates to procedures and devices for affixing the atrial appendages in an orientation that prevents subsequent formation of thrombus. The invention removes the appendage from the atrium by pulling on it and putting a loop around it to form a sack of the atrial appendage and then cut off from the rest of the heart.


U.S. Pat. No. 5,306,234 relates to a method for surgically closing the passage between the atrium and the atrial appendage or severing the atrial appendage.


U.S. Pat. Nos. 6,551,303 and 6,689,150 disclose barrier devices and filter devices respectively which may be deployed at the ostium of a left atrial appendage to block thrombus generated within the left atrial appendage from entering the left atrium and general circulation.


While current treatment methods are effective for minimizing migration of thrombus from the left atrial appendage into the general circulation, a need still exists for a percutaneous treatment option which does not result in the long term introduction of foreign matter which may provoke an inflammatory response.


SUMMARY

In some aspects, the invention relates to a left atrial appendage closure device comprising a plurality of centrally joined bioabsorbable struts forming an umbrella-like support structure which is concave when viewed from a distal end of the plurality of centrally joined bioabsorbable struts, wherein the umbrella-like support structure has a first radially compact configuration and a second expanded configuration in which second expanded configuration the umbrella-like support structure has a proximal circumferential dimension sized and adapted to span the ostium of a left atrial appendage and a distal extent sized and adapted to be contained within the left atrial appendage; a bioabsobable porous membrane which forms a porous cap coextensive with centrally joined portions of the bioabsorbable struts and which extends distally along at least a portion of the umbrella-like support structure sized and adapted to be contained within the left atrial appendage, wherein the porous membrane is bioabsorbable, the pores of the porous membrane are sized and adapted to retain thrombi within the left atrial appendage when the left atrial appendage closure device is deployed within the left atrial appendage, and the porous membrane includes a tissue growth promoting component. In some aspects, at least some of the bioabsorbable struts of the umbrella-like support structure may be joined near their distal ends to form a closed support structure cage.


In addition or alternatively, the invention relates to a left atrial appendage closure device wherein the bioabsorbable porous membrane is selected from the group consisting of a textile, a nonwoven, a braid, a laser cut sheet, an etched sheet, and a 3D printed article.


In some aspects, the bioabsorbable polymer of the plurality of centrally joined bioabsorbable struts and the polymer of the bioabsorbable porous membrane of the left atrial appendage closure device are selected from the group consisting of polyglycolic acid, polylactic acid, polycaprolactone, polyvalerolactone, poly(1,4-dioxane-2,3-dione), poly(1,3-dioxane-2-one), poly(p-dioxanone), poly(1,5-dioxepan-2-one), poly(β-R,S-malic acid), poly(α-malic acid), polyhydroxyalkanoates, and mixtures or copolymers thereof.


In some aspects of the invention, the polymer of the plurality of bioabsorbable struts is the same as the polymer of the bioabsorbable porous membrane.


In some aspects of the invention, the polymer of the plurality of centrally joined bioabsorbable struts is different from the polymer of the bioabsorbable porous membrane.


In certain aspects of the invention, the porous membrane includes a tissue growth promoting component selected from the group consisting of fibronectin, vascular endothelial growth factor, and fibroblast growth factor.


In some aspects of the invention the tissue growth promoting component of the left atrial appendage closure device is a layer on the porous membrane.


In certain aspects of the invention the tissue growth promoting component of the left atrial appendage closure device is dispersed within the bioabsorbable porous membrane.


In addition, the thicknesses of the struts of the plurality of centrally joined bioabsorbable struts and of the bioabsorbable porous membrane of the left atrial appendage device of the invention are selected to provide a controlled bioabsorption profile which minimizes release of particulate material.


In some aspects of the invention, the left atrial appendage closure device further comprises a hub which is attached to the centrally joined plurality of bioabsorbable struts and adapted to be releaseably attached to a distal end of a delivery shaft.


In addition or alternatively, the invention includes a method of manufacturing a left atrial appendage closure device comprising the steps of creating a plurality of centrally joined bioabsorbable struts forming an umbrella-like support structure and creating a porous bioabsorbable membrane which forms a porous cap coextensive with centrally joined portions of the bioabsorbable struts and extending distally along at least a portion of the umbrella-like support structure, wherein the porous membrane is fixedly attached to the plurality of centrally joined bioabsorbable struts forming an umbrella-like support structure and wherein the porous membrane includes a tissue growth promoting component. In some aspects of the method of manufacturing a left atrial appendage closure device, at least some of the distal ends of the bioabsorbable struts forming an umbrella-like support structure may be joined to form a closed support structure cage.


In certain aspects of the method of manufacturing a left atrial appendage closure device of the invention, the step of creating the plurality of centrally joined bioabsorbable struts forming an umbrella-like support structure includes one or more of welding, molding, vacuum forming, removing material from a solid workpiece, and 3D printing.


In some aspects of the method of manufacturing a left atrial appendage closure device, the step of creating the porous bioabsorbable membrane which forms a porous cap coextensive with centrally joined portions of the bioabsorbable struts and which extends distally along at least a portion of the umbrella-like support structure includes one or more of weaving, braiding, electrospraying, electrospinning, molding, vacuum forming, laser cutting, etching, and 3D printing.


In addition or alternatively, in the method of manufacturing a left atrial appendage closure device of the invention, the step of creating a plurality of centrally joined bioabsorbable struts forming an umbrella-like support structure and the step of creating a porous bioabsorbable membrane which forms a porous cap coextensive with centrally joined portions of the bioabsorbable struts and which extends distally along at least a portion of the umbrella-like support structure are carried out simultaneously to create a unitary left atrial appendage closure device. In some aspects, at least some of the bioabsorbable struts of the umbrella-like support structure may be joined near their distal ends to form a closed support structure cage.


In addition or alternatively the method of manufacturing a left atrial appendage closure device further comprises attaching a hub to the centrally joined bioabsorbable struts, said hub being adapted to be releaseably attached to a distal end of a delivery shaft.


In some aspects of the invention, left atrial appendage closure device comprises a plurality of bioabsorbable struts having a proximal end and a distal end which are joined at their proximal portions to form an umbrella-like support structure which is concave when viewed from a distal end of the plurality of proximally joined bioabsorbable struts, wherein the umbrella-like support structure has a first compact delivery configuration and a second expanded deployed configuration in which the umbrella-like support structure has a proximal circumferential dimension sized and adapted to span and engage the ostium of a left atrial appendage and a longitudinal extent sized and adapted to be contained within the left atrial appendage; a bioabsorbable porous cap coextensive with the joined proximal portions of the bioabsorbable struts and which extends distally therefrom along at least a portion of the umbrella-like support structure sized and adapted to be contained within the left atrial appendage, wherein the porous cap is bioabsorbable, the pores of the porous cap are sized and adapted to retain thrombi within the left atrial appendage when the left atrial appendage closure device is deployed within the left atrial appendage, and the porous cap includes a tissue growth promoting component. In some aspects, at least some of the bioabsorbable struts of the umbrella-like support structure may be joined near their distal ends to form a closed support structure cage.


In some aspects, the bioabsorbable porous cap of the left atrial appendage closure device of the invention is selected from the group consisting of a textile, a nonwoven, a braid, a laser cut sheet, an etched sheet, and a 3D printed article.


In addition, the bioabsorbable polymer of the plurality of proximally joined bioabsorbable struts and the polymer of the bioabsorbable porous cap of the left atrial appendage closure device of the invention are selected from the group consisting of polyglycolic acid, polylactic acid, polycaprolactone, polyvalerolactone, poly(1,4-dioxane-2,3-dione), poly(1,3-dioxane-2-one), poly(p-dioxanone), poly(1,5-dioxepan-2-one), poly(β-R,S-malic acid), poly(α-malic acid), polyhydroxyalkanoates, and mixtures or copolymers thereof.


In some aspects of the invention, the polymer of the plurality of bioabsorbable struts is the same as the polymer of the bioabsorbable porous cap.


In certain aspects of the invention, the plurality of proximally joined bioabsorbable struts and the bioabsorbable porous cap of the left atrial appendage closure device are integrally formed.


In some aspects of the invention, the polymer of the plurality of proximally joined bioabsorbable struts of left atrial appendage closure device of the invention is different from the polymer of the bioabsorbable porous cap.


In certain aspects of the invention, the tissue growth promoting component of the left atrial appendage closure device is selected from the group consisting of fibronectin, vascular endothelial growth factor, and fibroblast growth factor.


In some aspects of the invention, tissue growth promoting component of the left atrial appendage device of the invention is a layer on the bioabsorbable porous cap.


In addition or in the alternative, the tissue growth promoting component of the left atrial appendage device of the invention is dispersed within the bioabsorbable porous cap.


In addition or in the alternative, the tissue growth promoting component of the left atrial appendage device of the invention is absorbed within a surface layer of the bioabsorbable porous cap.


In some aspects of the invention, the thicknesses of the plurality of proximally joined bioabsorbable struts and the bioabsorbable porous cap of the left atrial appendage closure device are selected to provide a controlled bioabsorption profile which minimizes release of particulate material.


In addition or in the alternative, the left atrial appendage closure device further comprises a hub attached to the plurality of proximally joined bioabsorbable struts and adapted to be releaseably attached to a distal end of a delivery shaft.


In addition or in the alternative, the invention includes a method of manufacturing a left atrial appendage closure device comprising the steps of creating a plurality of bioabsorbable struts joined at their proximal portions to form a distally opening umbrella-like support structure and creating a porous bioabsorbable cap coextensive with proximally joined portions of the bioabsorbable struts and extending distally along at least a portion of the umbrella-like support structure, wherein the bioabsorbable porous cap is fixedly attached to the plurality of proximally joined bioabsorbable struts forming an umbrella-like support structure and wherein the bioabsorbable porous cap includes a tissue growth promoting component. In some aspects, at least some of the bioabsorbable struts of the umbrella-like support structure may be joined near their distal ends to form a closed support structure cage.


In certain aspects of the method of manufacturing a left atrial appendage closure device, the step of creating the plurality of bioabsorbable struts joined at their proximal portions to form a distally opening umbrella-like support structure includes one or more of welding, molding, vacuum forming, removing material from a solid workpiece, and 3D printing. In some aspects, at least some of the bioabsorbable struts of the umbrella-like support structure may be joined near their distal ends to form a closed support structure cage.


In some aspects of the method of manufacturing a left atrial appendage closure device of the invention, the step of creating the bioabsorbable porous cap which forms a porous cap coextensive with proximally joined portions of the bioabsorbable struts and which extends distally along at least a portion of the umbrella-like support structure includes one or more of weaving, braiding, electrospraying, electrospinning, molding, vacuum forming, laser cutting, etching, and 3D printing.


In the alternative or in addition, the method of manufacturing a left atrial appendage closure device of claim 28, wherein the steps of creating a plurality of bioabsorbable struts joined at their proximal portions to form a distally opening umbrella-like support structure and creating a porous bioabsorbable membrane which forms a porous cap coextensive with the plurality of bioabsorbable struts joined at their proximal portions to form a distally opening umbrella-like support structure which extends distally along at least a portion of the umbrella-like support structure are carried out simultaneously to create a unitary left atrial appendage closure device. In some aspects, at least some of the bioabsorbable struts of the umbrella-like support structure may be joined near their distal ends to form a closed support structure cage.


In some aspects of the method of manufacturing a left atrial appendage closure device of the invention, the bioabsorbable polymer of the plurality of bioabsorbable struts and of the bioabsorbable porous cap is selected from the group consisting of polyglycolic acid, polylactic acid, polycaprolactone, polyvalerolactone, poly(1,4-dioxane-2,3-dione), poly(1,3-dioxane-2-one), poly(p-dioxanone), poly(1,5-dioxepan-2-one), poly(β-R,S-malic acid), poly(α-malic acid), polyhydroxyalkanoates, and mixtures or copolymers thereof.


In certain aspects of the method of manufacturing a left atrial appendage closure device of the invention the tissue growth promoting component is selected from the group consisting of fibronectin, vascular endothelial growth factor, and fibroblast growth factor.


In addition or in the alternative, the method of manufacturing a left atrial appendage closure device of the invention further comprises a step of attaching a hub to the plurality of bioabsorbable struts joined at their proximal ends, said hub being adapted to be releaseably attached to a distal end of a delivery shaft.


In some aspects of the method of manufacturing a left atrial appendage closure device the invention, the hub is a bioabsorbable hub.





BRIEF DESCRIPTION OF DRAWINGS


FIG. 1A presents a lateral view of a left atrial appendage closure device of the invention.



FIG. 1B illustrates an alternate arrangement of the plurality of centrally joined struts of a left atrial appendage closure device of the invention.



FIG. 2 presents an axial view of the left atrial appendage closure device of FIG. 1A as seen from the distal end thereof.



FIG. 3 presents a partial cutaway view of a left atrial appendage closure device of the invention disposed in a distal portion of a delivery catheter.



FIG. 4 presents a detail view of a releasable connection between a delivery shaft and a hub of a left atrial appendage closure device of the invention.



FIG. 5 illustrates a plurality of centrally joined struts of a left atrial appendage closure device of the invention.



FIGS. 6A and 6B provide schematic cross-sectional views of portions of porous cap membranes of the invention which include a tissue growth promoting component.





DETAILED DESCRIPTION

The following description should be read with reference to the drawings wherein like reference numerals indicate like elements throughout the several views. The drawings, which are not necessarily to scale, are not intended to limit the scope of the claimed invention. The detailed description and drawings exemplify aspects of the claimed invention.


Although some suitable dimensions, ranges and/or values pertaining to various components, features and/or specifications are disclosed, one of skill in the art, incited by the present disclosure, would understand desired dimensions, ranges and/or values may deviate from those expressly disclosed unless the context clearly indicates an intended limitation.


All numbers are herein assumed to be modified by the term “about.” The recitation of numerical ranges by endpoints includes all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).


As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include the plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.


It is noted that references in the specification to “an aspect”, “some aspects”, “other aspects”, etc., indicate that the aspect described may include a particular feature, structure, or characteristic, but not every aspect may necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same aspect of the invention. Further, when a particular feature, structure, or characteristic is described in connection with an aspect, it would be within the knowledge of one skilled in the art to effect such feature, structure, or characteristic in connection with other embodiments whether or not explicitly described unless clearly stated to the contrary.



FIG. 1A shows a lateral view of an expanded self-expanding left atrial appendage closure device 100 and FIG. 2 shows a axial view of the same device as seen from the distal end, which device comprises a plurality of bioabsorbable struts 122, each having a proximal end and a distal end, which are joined at their proximal portions to form an umbrella-like support structure which is concave when viewed from a distal end of the plurality of proximally joined bioabsorbable struts; a porous cap 110 coextensive with the joined proximal portions of the bioabsorbable struts 122 and extending distally therefrom along at least a portion of the bioabsorbable struts 122. In some aspects, at least some of the bioabsorbable struts of the umbrella-like support structure may be joined near their distal ends to form a closed support structure cage.


Although the illustrated aspect of the invention has eight bioabsorbable struts 122, it will be appreciated that more or fewer bioabsorbable struts, for example, 4, 5, 6, 7, 9, 10, or 12 struts, may be employed if desired. Generally fewer struts may reduce the diameter of a collapsed configuration of a left atrial appendage closure device 100 to facilitate delivery, while the addition of more bioabsorbable struts 122 may tend to provide a smoother wall sealing contour by allowing individual bioabsorbable struts 122 flex to a greater or lesser extent to accommodate variations in the shape of an ostium. In some aspects of the invention, at least some of the bioabsorbable struts may be joined at their distal ends to form a closed cage support structure.


The proximal ends of the plurality of bioabsorbable struts 122 may assume a generally planar configuration adapted to span the ostium of a left atrial appendage before bending distally to provide a more cylindrical wall engaging portion. The joined proximal ends may form or include a hub 120 to be discussed in greater detail below. In some aspects of the invention, the hub 120 may be formed as a thickened region of the joined proximal ends of the plurality of bioabsorbable struts 122. Although shown in the figures as slightly protruding proximally from the porous cap 110 in the figures for clarity of illustration, it will be appreciated that the hub may be constructed to be flush with the porous cap 110 or even slightly recessed therefrom.


Bioabsorbable struts 122 may also include one or more optional barbs 124 to be discussed in greater detail later.


The invention contemplates a variety of cross-sectional shapes and cross-sectional areas distributed along the length of the struts which are selected to control the rate of bioabsorption in a manner which provides adequate support during endothelialization, provides rapid bioabsorption when support is no longer required, and which minimizes the release of portions of the biodegradable struts 122 and/or the porous cap 110 membrane which might otherwise constitute undesirable particulate matter debris within the circulatory system.


The bioabsorbable struts 122 and the resulting umbrella-like structure may be formed by any of the methods employed in the art to construct similar structures and may include injection molding, blow molding, machining, 3D printing and assembly from individual components. In certain aspects of the invention, the bioabsorbable struts 122 or 122′ and hub 120 may be formed as a separate membrane supporting structure as shown in FIG. 5. In some aspects of the invention, the bioabsorbable struts 122 may be formed from one or more of polyglycolic acid, polylactic acid, polycaprolactone, polyvalerolactone, poly(1,4-dioxane-2,3-dione), poly(1,3-dioxane-2-one), poly(p-dioxanone), poly(1,5-dioxepan-2-one), poly(β-R,S-malic acid), poly(α-malic acid), polyhydroxyalkanoates, mixtures or copolymers thereof, and the like. In an exemplary aspect, the bioabsorbable struts 122 may be formed from poly-4-hydroxybutyrate and copolymers thereof.


The porous cap 110 of FIGS. 1 and 2 may be viewed as providing a generally planar central region which is adapted to span an ostium of a left atrial appendage as well as transitioning to provide a generally cylindrical skirt which is adapted to lie along a lumen wall defined by a left atrial appendage and to improve the lateral sealing ability of the porous cap 110 within the left atrial appendage once the device is deployed.


The porous cap 110 is formed from a bioabsorbable membranous material which may comprise one or more of polyglycolic acid, polylactic acid, polycaprolactone, polyvalerolactone, poly(1,4-dioxane-2,3-dione), poly(1,3-dioxane-2-one), poly(p-dioxanone), poly(1,5-dioxepan-2-one), poly(β-R,S-malic acid), poly(α-malic acid), polyhydroxyalkanoates, mixtures or copolymers thereof, and the like. In an exemplary aspect, the porous cap 110 membrane may be formed from poly-4-hydroxybutyrate and copolymers thereof.


The porous cap 110 membrane may be a textile, a nonwoven, a braid, a laser cut sheet, an etched sheet or a 3D printed article. In some aspects, the porous cap 110 membrane may be formed by one or more of weaving, braiding, electrospraying, electrospinning, molding, vacuum forming, laser cutting, etching, and 3D printing. While the pores of the porous cap 110 membrane have been depicted as through pores for ease of illustration in some of the figures, it will be appreciated that for the purpose of promoting tissue ingrowth of endothelial tissue, some or all of the porosity may be disposed at or near the surface of the porous cap 110 membrane. Although illustrated in the figures as disposed over the bioabsorbable struts 122, it will be appreciated that the porous cap 110 membrane may in the alternative be disposed within a support structure provided by bioabsorbable struts 122.


It also will be appreciated that it may be convenient to form the plurality of centrally joined bioabsorbable struts 122 and the porous cap 110 membrane simultaneously as an integrally formed object. In those aspects, it may be desirable to include one or more additional components of the left atrial appendage closure device 100 such as hub 120, barbs 124 or their equivalents, a tissue growth promoter 112, 114, and the like in the same forming operation. In addition, in such aspects the portions of the bioabsorbable struts 122 which are coextensive with the porous cap 110 membrane may be present as thickened portions of the porous cap 110 membrane rather than as distinctly separate features.


The hub 120, barbs 124 or their equivalents, a tissue growth promoter 112, 114, and the like may also be introduced at different stages of the manufacturing operation if desired. Similarly, it may be desirable or convenient to use the same or different bioabsorbable polymers for various components of the left atrial appendage closure device as well as the same or different manufacturing processes for the fabrication of individual components to be assembled in separate steps of a manufacturing method.


In the aspect of the invention illustrated in FIGS. 1 and 2, each bioabsorbable strut 122 includes an optional barb 124 which is sized and adapted to engage adjacent tissue to minimize migration of a deployed device. Although one barb 124 is shown on each bioabsorbable strut 122, one of ordinary skill in the art would appreciate that this arrangement is only illustrative of an aspect of the invention. In other aspects, a strut or struts may have 0, 2, 3, or more barbs per bioabsorbable strut 122 and not every bioabsorbable strut 122 needs to have the same number of barbs 124 as its immediate neighbors. The simple barb 124 of FIGS. 1 and 2 is intended to be representative of other structures known in the art to inhibit migration of an implanted device. For example, the simple barb 124 of FIGS. 1 and 2 may be replaced by a two-tipped barb having one tip disposed generally in a proximal direction along the associated bioabsorbable strut while a second tip is disposed generally in a distal direction along the associated bioabsorbable strut 122. Similarly, the barb 124 may be replaced with a roughened segment of exposed bioabsorbable strut 122 such that each protrusion from the roughened segment of exposed bioabsorbable strut 122 may be viewed as a tip of a barb 124. Some barbs 124 may be integrally formed with the associated strut while other barbs 124 may be formed separately and attached to the bioabsorbable strut 122. It will be appreciated that although the exemplary barbs 124 are illustrated as located at the distal margin of the porous cap 110 membrane, barbs 124 or their equivalents may be distributed at other locations along the associated bioabsorbable strut 122 and may extend outward from the surface of the porous cap 110 membrane as well as outward from more distal portions of the bioabsorbable struts 122. As discussed above, barbs 124 or their equivalents, if present, also may be formed from the previously identified bioabsorbable polymer(s) using the known manufacturing processes.


In the interest of promoting tissue growth into and across the portion of the porous cap 110 membrane located at the ostium of the left atrial appendage to permanently seal the ostium prior to the full bioabsorption of the left atrial appendage closure device 100, the devices include a tissue growth promoting component 112, 114 which may be dispersed throughout the porous cap 110 membrane as shown in FIG. 6A, preferentially absorbed near one or both surfaces of the porous cap 110 membrane, and/or applied as a coating to one or both surfaces of the porous cap 110 membrane as shown if FIG. 6B. If desired or convenient, the tissue growth promoting component 112, 114 may also be present within or applied to other components of the left atrial appendage closure device 100 such as the bioabsorbable struts 122 and barbs 124 or their equivalents.


In a further aspect related to the manufacturing of a left atrial appendage closure device 100, a support structure shown in FIG. 5 provided by bioabsorbable struts 122 comprising poly-4-hydroxybutyrate may be formed separately by, for example, injection molding and then positioned about a mandrel. In an alternate aspect of the manufacturing method, a support structure shown in FIG. 1B, in which at least some of the bioabsorbable struts 122′ may also be joined at their distal end. In a separate step, a porous cap 110 membrane may be formed over a portion of the bioabsorbable struts 122 and the mandrel by electrospinning filaments of poly-4-hydroxybutyrate. In some aspects, the bioabsorbable struts 122 may be removed from the mandrel and a porous cap 110 membrane may be formed over a portion of the bioabsorbable struts 122 and the mandrel by electrospinning filaments of poly-4-hydroxybutyrate. The filaments may comprise a dispersed tissue growth promoter 112 as shown somewhat schematically in FIG. 6A or a tissue growth promoter 114 may be applied to the porous cap 110 membrane as a coating or as an adsorbed layer, as shown in FIG. 6B, in a later step.


The bioabsorbable left atrial appendage closure devices 100 of FIGS. 1 and 2 may be delivered to the left atrial appendage using delivery catheters and approaches of the art. For example, the bioabsorbable left atrial appendage closure devices 100 of FIGS. 1 and 2 may be caused to assume a first compact configuration adapted to be received within the distal end of a delivery catheter 200, as shown in FIG. 3, prior to being advanced to the deployment site where the devices may be expelled by advancement of delivery shaft 230 and/or withdrawal of delivery catheter 200. In such aspects, the bioabsorbable left atrial appendage closure device 100 may include a proximal hub 120 adapted to releasably mate with a delivery shaft 230, one aspect of which is illustrated in FIG. 4.


In the illustrated aspect of FIG. 4, the distal tip 240 of the delivery shaft 230 includes a male threaded portion and the corresponding mating hub 120 of the bioabsorbable left atrial appendage closure device 100 includes a female threaded aperture adapted to threadably engage the distal tip 240 for delivery through and from the delivery catheter 200, including possible recollapse and repositioning within the delivery site before rotation of the deliver shaft and distal tip 240 unscrews the distal tip 240 from the mating hub 120 of the bioabsorbable left atrial appendage closure device 100. It will be appreciated that engagement between the delivery site wall upon self-expansion of the bioabsorbable left atrial appendage closure device 100 to assume a second expanded configuration will provide the resistance necessary to allow the distal tip 240 to unscrew from the mating hub 120.


It also will be appreciated that other releasable mating connectors known in the art may be used. For example, the female threaded portion of the releasable mating connector may be formed within distal tip 240, while the hub 120 includes a mating male threaded portion. In the alternative, friction fit couplings, pin and loop connectors, and even magnetic couplers may be used with due regard for bioabsorbability of the components of the hub 120. The delivery catheter 200 and/or the delivery shaft 230 may include radiopaque markers to aid in positioning the left atrial appendage closure device 100 within the left atrial appendage.


Although the illustrative examples described above relate to closure of a left atrial appendage, it is also contemplated that the device may be used close other ostia such as that of an aneurysm. In such an aspect, the size and shape of the generally planar central region of the proximal portions of the bioabsorbable struts and porous cap as well as the distal extent of the device as a whole may be modified to better match the ostium and depth of the aneurysm or other lumen.


Various modifications and alterations of this invention will become apparent to those skilled in the art without departing from the scope and principles of this invention, and it should be understood that this invention is not to be unduly limited to the illustrative embodiments set forth hereinabove. All publications and patents are herein incorporated by reference to the same extent as if each individual publication or patent was specifically and individually indicated to be incorporated by reference.

Claims
  • 1. A left atrial appendage closure device comprising: a plurality of bioabsorbable struts having a proximal end and a distal end which are joined at their proximal portions to form an umbrella-like support structure which is concave when viewed from a distal end of the plurality of bioabsorbable struts,wherein the umbrella-like support structure has a first compact delivery configuration and a second expanded deployed configuration in which the umbrella-like support structure has a proximal circumferential dimension sized and adapted to span and engage an ostium of a left atrial appendage and a longitudinal extent sized and adapted to be contained within the left atrial appendage;a bioabsorbable porous cap coextensive with the joined proximal portions of the bioabsorbable struts and which extends distally therefrom along at least a portion of the umbrella-like support structure sized and adapted to be contained within the left atrial appendage,wherein the pores of the bioabsorbable porous cap are sized and adapted to retain thrombi within the left atrial appendage when the left atrial appendage closure device is deployed within the left atrial appendage, and the bioabsorbable porous cap includes a tissue growth promoting component,wherein the plurality of bioabsorbable struts and the bioabsorbable porous cap are integrally formed from a single polymer.
  • 2. The left atrial appendage closure device of claim 1, wherein the bioabsorbable porous cap is selected from the group consisting of a textile, a nonwoven, a braid, a laser cut sheet, an etched sheet, and a 3D printed article.
  • 3. The left atrial appendage closure device of claim 1, wherein the single polymer is selected from the group consisting of polyglycolic acid, polylactic acid, polycaprolactone, polyvalerolactone, poly(1,4-dioxane-2,3-dione), poly(1,3-dioxane-2-one), poly(p-dioxanone), poly(1,5-dioxepan-2-one), poly(P-R,S-malic acid), poly(α-malic acid), polyhydroxyalkanoates, and mixtures or copolymers thereof.
  • 4. The left atrial appendage closure device of claim 1, wherein the tissue growth promoting component is selected from the group consisting of fibronectin, vascular endothelial growth factor, and fibroblast growth factor.
  • 5. The left atrial appendage closure device of claim 1, wherein tissue growth promoting component is a layer on the bioabsorbable porous cap.
  • 6. The left atrial appendage closure device of claim 1, wherein tissue growth promoting component is dispersed within the bioabsorbable porous cap.
  • 7. The left atrial appendage closure device of claim 1, wherein tissue growth promoting component is absorbed within a surface layer of the bioabsorbable porous cap.
  • 8. The left atrial appendage closure device of claim 1, wherein thicknesses of the plurality of bioabsorbable struts and the bioabsorbable porous cap are selected to provide a controlled bioabsorption profile which minimizes release of particulate material.
  • 9. The left atrial appendage closure device of claim 1, further comprising a hub attached to the plurality of bioabsorbable struts and adapted to be releaseably attached to a distal end of a delivery shaft.
RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 62/254,969, filed Nov. 13, 2015.

US Referenced Citations (275)
Number Name Date Kind
1178283 French Jun 1876 A
1967318 Monahan Jul 1934 A
3844302 Klein Oct 1974 A
3874388 King et al. Apr 1975 A
4007743 Blake Feb 1977 A
4341218 Ü Jul 1982 A
4585000 Hershenson Apr 1986 A
4603693 Conta et al. Aug 1986 A
4665906 Jervis May 1987 A
4710192 Liotta et al. Dec 1987 A
4832055 Palestrant May 1989 A
4873978 Ginsburg Oct 1989 A
4917089 Sideris Apr 1990 A
4921484 Hillstead May 1990 A
5037810 Saliba, Jr. Aug 1991 A
5041090 Scheglov et al. Aug 1991 A
5041093 Chu Aug 1991 A
5042707 Taheri Aug 1991 A
5053009 Herzberg Oct 1991 A
5064435 Porter Nov 1991 A
5078736 Behl Jan 1992 A
5108420 Marks Apr 1992 A
5171259 Inoue Dec 1992 A
5171383 Sagaye et al. Dec 1992 A
5176692 Wilk et al. Jan 1993 A
5192301 Kamiya et al. Mar 1993 A
5256146 Ensminger et al. Oct 1993 A
5258042 Mehta Nov 1993 A
5284488 Sideris Feb 1994 A
5306234 Johnson Apr 1994 A
5334217 Das Aug 1994 A
5350399 Erlebacher et al. Sep 1994 A
5353784 Nady-Mohamed Oct 1994 A
5370657 Irie Dec 1994 A
5375612 Cottenceau et al. Dec 1994 A
5417699 Klein et al. May 1995 A
5421832 Lefebvre Jun 1995 A
5425744 Fagan et al. Jun 1995 A
5433727 Sideris Jul 1995 A
5443454 Tanabe et al. Aug 1995 A
5451235 Lock et al. Sep 1995 A
5464408 Duc Nov 1995 A
5469867 Schmitt Nov 1995 A
5490856 Person et al. Feb 1996 A
5509899 Fan et al. Apr 1996 A
5522822 Phelps et al. Jun 1996 A
5522836 Palermo Jun 1996 A
5527322 Klein et al. Jun 1996 A
5527338 Purdy Jun 1996 A
5591196 Marin et al. Jan 1997 A
5614204 Cochrum Mar 1997 A
5634936 Linden et al. Jun 1997 A
5634942 Chevillon et al. Jun 1997 A
5637097 Yoon Jun 1997 A
5643292 Hart Jul 1997 A
5649953 Lefebvre Jul 1997 A
5662671 Barbut et al. Sep 1997 A
5669933 Simon et al. Sep 1997 A
5681347 Cathcart et al. Oct 1997 A
5690671 McGurk et al. Nov 1997 A
5693067 Purdy Dec 1997 A
5695525 Mulhauser et al. Dec 1997 A
5702421 Schneidt Dec 1997 A
5709224 Behl et al. Jan 1998 A
5709707 Lock et al. Jan 1998 A
5725552 Kotula et al. Mar 1998 A
5725568 Hastings Mar 1998 A
5733294 Forber et al. Mar 1998 A
5735290 Sterman et al. Apr 1998 A
5749883 Halpern May 1998 A
5749894 Engelson May 1998 A
5766219 Horton Jun 1998 A
5769816 Barbut et al. Jun 1998 A
5776097 Massoud Jul 1998 A
5782860 Epstein et al. Jul 1998 A
5810874 Lefebvre Sep 1998 A
5823198 Jones et al. Oct 1998 A
5830228 Knapp et al. Nov 1998 A
5836913 Orth et al. Nov 1998 A
5836968 Simon et al. Nov 1998 A
5846260 Maahs Dec 1998 A
5846261 Kotula et al. Dec 1998 A
5849005 Garrison et al. Dec 1998 A
5851232 Lois Dec 1998 A
5855597 Jayaraman Jan 1999 A
5865791 Whayne et al. Feb 1999 A
5865802 Yoon et al. Feb 1999 A
5868702 Stevens et al. Feb 1999 A
5868708 Hart et al. Feb 1999 A
5876367 Kaganov et al. Mar 1999 A
5882340 Yoon Mar 1999 A
5885258 Sachdeva et al. Mar 1999 A
5895399 Barbut et al. Apr 1999 A
5902289 Swartz et al. May 1999 A
5904703 Gilson May 1999 A
5906207 Shen May 1999 A
5910154 Tsugita et al. Jun 1999 A
5911734 Tsugita et al. Jun 1999 A
5916236 Muijs Van de Moer et al. Jun 1999 A
5928192 Maahs Jul 1999 A
5928260 Chin et al. Jul 1999 A
5931818 Werp et al. Aug 1999 A
5935147 Kensey et al. Aug 1999 A
5935148 Villar et al. Aug 1999 A
5941249 Maynard et al. Aug 1999 A
5944738 Amplatz et al. Aug 1999 A
5947997 Pavcnik et al. Sep 1999 A
5951589 Epstein et al. Sep 1999 A
5954694 Sunseri Sep 1999 A
5957940 Tanner et al. Sep 1999 A
5976174 Ruiz Nov 1999 A
5980514 Kupiecki et al. Nov 1999 A
5980555 Barbut et al. Nov 1999 A
5989281 Barbut et al. Nov 1999 A
5993469 McKenzie et al. Nov 1999 A
5997557 Barbut et al. Dec 1999 A
6007523 Mangosong Dec 1999 A
6007557 Ambrisco et al. Dec 1999 A
6010517 Baccaro Jan 2000 A
6010522 Barbut et al. Jan 2000 A
6024754 Engelson Feb 2000 A
6024755 Addis Feb 2000 A
6024756 Huebsch et al. Feb 2000 A
6027520 Tsugita et al. Feb 2000 A
6033420 Hahnen Mar 2000 A
6042598 Tsugita et al. Mar 2000 A
6048331 Tsugita et al. Apr 2000 A
6051014 Jang Apr 2000 A
6051015 Maahs Apr 2000 A
6056720 Morse May 2000 A
6068621 Balceta et al. May 2000 A
6074357 Kaganov et al. Jun 2000 A
6079414 Roth Jun 2000 A
6080182 Shaw et al. Jun 2000 A
6080183 Tsugita et al. Jun 2000 A
6083239 Addis Jul 2000 A
6132438 Fleischman et al. Oct 2000 A
6136016 Barbut et al. Oct 2000 A
6139527 Laufer et al. Oct 2000 A
6152144 Lesh et al. Nov 2000 A
6161543 Cox et al. Dec 2000 A
6193739 Chevillon et al. Feb 2001 B1
6203531 Ockuly et al. Mar 2001 B1
6231561 Frazier et al. May 2001 B1
6231589 Wessman et al. May 2001 B1
6290674 Roue et al. Sep 2001 B1
6328727 Frazier et al. Dec 2001 B1
6328755 Marshall Dec 2001 B1
6419669 Frazier et al. Jul 2002 B1
6436088 Frazier et al. Aug 2002 B2
6458100 Roue et al. Oct 2002 B2
6533782 Howell et al. Mar 2003 B2
6537300 Girton Mar 2003 B2
6551303 Van Tassel et al. Apr 2003 B1
6561969 Frazier et al. May 2003 B2
6589214 McGuckin et al. Jul 2003 B2
6595989 Schaer Jul 2003 B1
6641557 Frazier et al. Nov 2003 B1
6641564 Kraus Nov 2003 B1
6650923 Lesh et al. Nov 2003 B1
6652555 Van tassel et al. Nov 2003 B1
6652556 Van tassel et al. Nov 2003 B1
6673053 Wang et al. Jan 2004 B2
6689150 Van tassel et al. Feb 2004 B1
6702825 Frazier et al. Mar 2004 B2
6712804 Roue et al. Mar 2004 B2
6730108 Van Tassel et al. May 2004 B2
6746472 Frazier et al. Jun 2004 B2
6755812 Peterson et al. Jun 2004 B2
6949113 Van Tassel et al. Sep 2005 B2
6994092 Van Der Burg et al. Feb 2006 B2
7011671 Welch Mar 2006 B2
7025756 Frazier et al. Apr 2006 B2
7044134 Khairkhahan et al. May 2006 B2
7115110 Frazier et al. Oct 2006 B2
7128073 Van Der Burg et al. Oct 2006 B1
7152605 Khairkhahan et al. Dec 2006 B2
7169164 Borillo et al. Jan 2007 B2
7192439 Khairkhahan et al. Mar 2007 B2
7338514 Wahr et al. Mar 2008 B2
7427279 Frazier et al. Sep 2008 B2
7544381 Kangas Jun 2009 B2
7549983 Roue et al. Jun 2009 B2
7566336 Corcoran et al. Jul 2009 B2
7597704 Frazier et al. Oct 2009 B2
7674256 Marrouche et al. Mar 2010 B2
7713282 Frazier et al. May 2010 B2
7722641 Van Der Burg et al. May 2010 B2
7727189 Van tassel et al. Jun 2010 B2
7735493 Van Der Burg et al. Jun 2010 B2
7780683 Roue et al. Aug 2010 B2
7914809 Atanasoska et al. Mar 2011 B2
7972359 Kreidler Jul 2011 B2
8034061 Amplatz et al. Oct 2011 B2
8043305 Frazier et al. Oct 2011 B2
8043329 Khairkhahan et al. Oct 2011 B2
8048060 Griffin et al. Nov 2011 B2
8052715 Quinn et al. Nov 2011 B2
8080032 Van Der Burg et al. Dec 2011 B2
8197496 Roue et al. Jun 2012 B2
8197527 Borillo et al. Jun 2012 B2
8221384 Frazier et al. Jul 2012 B2
8221445 Van Tassel et al. Jul 2012 B2
8287563 Khairkhahan et al. Oct 2012 B2
8313505 Amplatz et al. Nov 2012 B2
8323309 Khairkhahan et al. Dec 2012 B2
8398670 Amplatz et al. Mar 2013 B2
8454633 Amplatz et al. Jun 2013 B2
8523897 Van Der Burg et al. Sep 2013 B2
8535343 Van Der Burg et al. Sep 2013 B2
20010039434 Frazier et al. Nov 2001 A1
20010039435 Roue et al. Nov 2001 A1
20010039436 Frazier et al. Nov 2001 A1
20010041914 Frazier et al. Nov 2001 A1
20010041915 Roue et al. Nov 2001 A1
20010049492 Frazier et al. Dec 2001 A1
20020111647 Khairkhahan Aug 2002 A1
20030023266 Borillo et al. Jan 2003 A1
20030057156 Peterson et al. Mar 2003 A1
20030195555 Khairkhahan et al. Oct 2003 A1
20030199923 Khairkhahan et al. Oct 2003 A1
20030204203 Khairkhahan et al. Oct 2003 A1
20030212432 Khairkhahan et al. Nov 2003 A1
20030220667 Van Der Burg et al. Nov 2003 A1
20040034366 Van Der Burg et al. Feb 2004 A1
20040044361 Frazier et al. Mar 2004 A1
20040098031 Van Der Burg et al. May 2004 A1
20040186486 Roue et al. Sep 2004 A1
20040215169 Li Oct 2004 A1
20040215230 Frazier et al. Oct 2004 A1
20040220595 Frazier et al. Nov 2004 A1
20040230222 Van Der Burg et al. Nov 2004 A1
20050004652 Van Der Burg et al. Jan 2005 A1
20050038470 Van Der Burg et al. Feb 2005 A1
20050070952 Devellian Mar 2005 A1
20050125032 Whisenant et al. Jun 2005 A1
20050149115 Roue et al. Jul 2005 A1
20050177182 Van Der Burg et al. Aug 2005 A1
20050192627 Whisenant et al. Sep 2005 A1
20050203568 Burg et al. Sep 2005 A1
20050234543 Glaser et al. Oct 2005 A1
20050288706 Widomski Dec 2005 A1
20060184234 Frazier et al. Aug 2006 A1
20060206148 Khairkhahan et al. Sep 2006 A1
20070066993 Kreidler Mar 2007 A1
20070066994 Blaeser et al. Mar 2007 A1
20070080188 Spence et al. Apr 2007 A1
20070083227 Van Der Burg et al. Apr 2007 A1
20070112380 Figulla et al. May 2007 A1
20070129753 Quinn et al. Jun 2007 A1
20070135826 Zaver et al. Jun 2007 A1
20070162048 Quinn et al. Jul 2007 A1
20080071307 DeBruyne Mar 2008 A1
20080071350 Stinson Mar 2008 A1
20080071358 Weber et al. Mar 2008 A1
20090028785 Clarke Jan 2009 A1
20090098176 Helmus et al. Apr 2009 A1
20100069838 Weber et al. Mar 2010 A1
20100087783 Weber et al. Apr 2010 A1
20110054515 Bridgeman et al. Mar 2011 A1
20110218566 Van Der Burg et al. Sep 2011 A1
20120029541 Frazier et al. Feb 2012 A1
20120029553 Quinn et al. Feb 2012 A1
20120035643 Khairkhahan et al. Feb 2012 A1
20120065662 Van Der Burg et al. Mar 2012 A1
20120065667 Javois Mar 2012 A1
20120095396 Radhakrishnan et al. Apr 2012 A1
20120232585 Roue et al. Sep 2012 A1
20120239077 Zaver et al. Sep 2012 A1
20120239083 Kreidler Sep 2012 A1
20130012982 Khairkhahan et al. Jan 2013 A1
20130018413 Oral Jan 2013 A1
20130110154 Van Der Burg et al. May 2013 A1
20130138138 Clark May 2013 A1
20140074151 Tischler et al. Mar 2014 A1
Foreign Referenced Citations (41)
Number Date Country
102005053958 May 2007 DE
102008015781 Sep 2011 DE
1223890 Apr 2004 EP
1227770 Sep 2004 EP
1616530 Oct 2008 EP
1659988 Feb 2010 EP
1620020 Sep 2010 EP
1135068 Jun 2011 EP
1441649 Aug 2011 EP
2014533970 Dec 2014 JP
2015509752 Apr 2015 JP
913712 Jul 1993 WO
9721402 Jun 1997 WO
9726939 Jul 1997 WO
9728749 Aug 1997 WO
9802100 Jan 1998 WO
9817187 Apr 1998 WO
9823322 Jun 1998 WO
9907289 Feb 1999 WO
9908607 Feb 1999 WO
9912478 Mar 1999 WO
9930640 Jun 1999 WO
9959479 Nov 1999 WO
0001308 Jan 2000 WO
0027292 May 2000 WO
0053120 Sep 2000 WO
0121247 Mar 2001 WO
0126726 Apr 2001 WO
0130266 May 2001 WO
0130267 May 2001 WO
0130268 May 2001 WO
2002071977 Sep 2002 WO
2003007825 Jan 2003 WO
2003063732 Aug 2003 WO
2004096060 Nov 2004 WO
2007054116 May 2007 WO
2007140797 Dec 2007 WO
2008125689 Oct 2008 WO
2009091425 Jul 2009 WO
2011147783 Dec 2011 WO
2014210263 Dec 2014 WO
Non-Patent Literature Citations (14)
Entry
International search report for PCT/US2016/061543. 6 pages, dated May 18, 2017. (Year: 2017).
“Filter”. definition by Oxford Dicitonary <https://www.lexico.com/en/definition/filter> accessed on Aug. 15, 2019 (Year: 2019).
“Absorb” definition by Merriam-Webster Dictionary <https://www.merriam-webster.com/dictionary/absorb> accessed on Aug. 15, 2019 Year: 2019).
Cragg et al., “A New Percutaneous Vena Cava Filter,” ALJ, 141: 601-604, Sep. 1983.
Cragg et al., “Nonsurgical Placement of Arterial Endoprothesis: A New Technique Using Nitinol Wire,” Radiology, 147(1): 261-263, Apr. 1983.
Lock et al., “Transcatheter Closure of Atrial Septal Defects,” Circulation, 79(5): 1091-1099, May 1989.
Lock et al., “Transcatheter Umbrella Closure of Congenital Heart Defects,” Circulation, 75(3): 593-599, 1987.
Rashkind et al., “Nonsurgical Closure of Patent Ductus Arteriosus: Clinical Application of the Rashking PDA Occluder System,” Circulation, 75(3): 583-592, 1987.
Ruttenberg, “Nonsurgical Therapy of Cardiac Disorders,” Pediatric Consult, 5(2), 1986.
Sugita et al., “Nonsurgical Implantation of a Vascular Ring Prothesis Using Thermal Shape Memory Ti/Ni Alloy (Nitnol Wire),” Trans. Am. Soc. Artif. Intern. Organs, XXXII: 30-34, 1986.
Wessel et al., “Outpatient Closure of the Patent Ductus Arteriosus,” Circulation, 77(5): 1068-1071, 1988.
Khattab et al., “Transcatheter Devices for Left Atrial Appendage Occlusion,” Cardiovascular Medicine, 13(4): 130-134, 2010.
Amplatzer Vascular Plug Family, http://web.archive.org/web/20100514232852/http://international.amplatzer.com/InternationalProducts/VascularPlugFamily/tabid/528/Default.aspx, accessed Oct. 9, 2013, and said, by the Wayback Machine, to have been archived on May 14, 2010.
Amplatzer Cardiac Plug, http://web.archive.org/web/20090809150223/http:/international.amplatzer.com/international_products/CardiacPlug/tabid/815/default.aspx, accessed Oct. 9, 2013, and said, by the Wayback Machine, to have been archived on Aug. 9, 2009.
Related Publications (1)
Number Date Country
20170135801 A1 May 2017 US
Provisional Applications (1)
Number Date Country
62254969 Nov 2015 US